^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TY-0540

    i
    Other names: TY-0540, TYK-00540, TY 0540, TYK 00540, TY0540, TYK00540
    Associations

    News

    Trials
    Company:
    TYK Medicines
    Drug class:
    CDK4 inhibitor, CDK6 inhibitor, CDK2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    10ms
    ASOTIAPWST: A Study of TYK-00540 in Adult Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=156, Recruiting, TYK Medicines, Inc
    New P1 trial
    |
    TY-0540
    over1year
    TY-0540, a highly potent CDK2/4/6 inhibitor, attenuates acquired resistance against CDK4/6 inhibition (AACR 2023)
    To test the effectiveness of the clinical candidate compound on CDK4/6i resistance models, two Palbociclib resistant cell populations (T47D-R, HCC1428-R) were in-house generated via gradient exposure of the cells to Palbociclib. #Meihua Li and Chengshan Niu contributed equally to this work. *Jun Li, Meihua Li and Chengshan Niu are the correspondent authors.
    Preclinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCNE1 (Cyclin E1) • CDK7 (Cyclin Dependent Kinase 7) • CDK9 (Cyclin Dependent Kinase 9) • FOXM1 (Forkhead Box M1) • CDK1 (Cyclin-dependent kinase 1) • E2F1 (E2F transcription factor 1)
    |
    HER-2 negative • CCNE1 amplification • MYC expression
    |
    Ibrance (palbociclib) • TY-0540